Xenon Pharmaceuticals Inc. (XENE) Stock Grade

About Xenon Pharmaceuticals Inc.'s fundamentals

Xenon Pharmaceuticals is a biotechnology company with a market capitalization of $3.5 billion that is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -4612.1%. The company generated no year-over-year revenue growth, indicating a stagnant top line during the most recent period. With no dividend yield and negative profitability metrics, the company is not yet generating returns for equity investors. As a development-stage biotech firm, Xenon's financial performance reflects the capital-intensive and often loss-making nature of the industry before successful drug commercialization.